A practical reference on chronic hepatitis B: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-29 and is reviewed periodically as new material appears.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
=== 25 December === The RSF claimed to have taken Kornoi in North Darfur, which was denied by the JDF. The RSF accused the SAF of carrying out an attack on a fuel market in Nyala that left an unspecified number of casualties.
=== Reinke's edema === A voice pathology called Reinke's edema, swelling due to abnormal accumulation of fluid, occurs in the superficial lamina propria or Reinke's space. This causes the vocal fold mucosa to appear floppy with excessive movement of the cover that has been described as looking like a loose sock. The greater mass of the vocal folds due to increased fluid lowers the fundamental frequency during phonation.
A key component in fleet management systems, is the vehicle tracking component. This component is usually GPS-based, but sometimes it can be based on GLONASS or a cellular triangulation platform. Once vehicle location, direction and speed are determined from the GPS components, additional tracking capabilities transmit this information to a fleet management software application. Methods for data transmission include both terrestrial and satellite. Satellite tracking communications, while more expensive, are critical if vehicle tracking is to work in remote environments without interruption. Users can see actual, real-time locations of their fleet on a map. This is often used to quickly respond on events in the field. In the European Union, the Data Act, which came into application in September 2025, requires manufacturers of connected vehicles to provide fleet operators with access to vehicle-generated data, enabling integration with third-party fleet management platforms.
=== Liquid crystals, colloidal glasses, and hydrogels === Owed to their anisotropic shape and surface charge, nanocelluloses (mostly rigid CNCs) have a high excluded volume and self-assemble into cholesteric liquid crystals beyond a critical volume fraction. Nanocellulose liquid crystals are left-handed due to the right-handed twist on particle level. Nanocellulose phase behavior is susceptible to ionic charge screening. An increase in ionic strength induces the arrest of nanocellulose dispersions into attractive glasses. At further increasing ionic strength, nanocelluloses aggregate into hydrogels. The interactions within nanocelluloses are weak and reversible, wherefore nanocellulose suspensions and hydrogels are self-healing and may be applied as injectable materials or 3D printing inks.
with equality in the equilateral case. More strongly, Barrow's inequality states that if the interior bisectors of the angles at interior point P (namely, of ∠APB, ∠BPC, and ∠CPA) intersect the triangle's sides at U, V, and W, then
Sources: en.wikipedia.org
=== Peptides === Cell Surface Peptides provide one way to introduce drug delivery into a target cell. This method is accomplished by the peptide binding to a target cells surface receptors, in a way that bypasses immune defenses that would otherwise compromise a slower delivery, without causing harm to the host. In particular, peptides, such as intercellular adhesion molecule-1, have shown a great deal of binding ability in a target cell. This method has shown a degree of efficacy in treating both autoimmune diseases as well as forms of cancer as a result of this binding affinity. Peptide mediated delivery is also of promise due to the low cost of creating the peptides as well as the simplicity of their structure.
== Career == Larsen worked for more than 35 years at DuPont. In her research in mass spectrometry, she worked with a number of ionization sources, from electrospray ionization, matrix-assisted laser desorption/ionization, solid probe introduction with corona discharge ionization, to laserspray ionization. Her fluorinated polymer extraction method, the Larsen method, is required by the Environmental Protection Agency for consumer safety. She is a consultant at Larsen Scientific Consulting. She serves on the editorial advisory board of Spectroscopy. She was an editor for the Journal of the American Society for Mass Spectrometry. She served on a number of board positions for the American Society for Mass Spectrometry: treasurer (1992-1994), vice president for programs (2004-2006), president (2006-2008), and past president (2008-2010). She was elected as an American Chemical Society Fellow in 2017.
Several critics complained about the required usage of the program Steam, the requirement to create an account, register the products, and permanently lock them to the account before being allowed to play, along with installation difficulties and lack of support.
Fibronectin type III domain-containing protein 5, the precursor of irisin, is a type I transmembrane glycoprotein that is encoded by the FNDC5 gene. Irisin is a cleaved version of FNDC5, named after the Greek messenger goddess Iris. Fibronectin domain-containing protein 5 is a membrane protein comprising a short cytoplasmic domain, a transmembrane segment, and an ectodomain consisting of a ~100 kDa fibronectin type III (FNIII) domain.
Sources: en.wikipedia.org
The research was taken up by Wilhelm Kühne, who named the pigment rhodopsin, also known as "visual purple." Kühne confirmed that rhodopsin is extremely sensitive to light, and thus enables vision in low-light conditions, and that it was this chemical decomposition that stimulated nerve impulses to the brain. Research stalled until after identification of "fat-soluble vitamin A" as a dietary substance found in milkfat but not lard, would reverse night blindness and xerophthalmia. In 1925, Fridericia and Holm demonstrated that vitamin A deficient rats were unable to regenerate rhodopsin after being moved from a light to a dark room.
== Discovery == The first descriptions of the MHC were made by British immunologist Peter Gorer in 1936. MHC genes were first identified in inbred mice strains. Clarence Little transplanted tumors across different strains and found rejection of transplanted tumors according to strains of host versus donor. George Snell selectively bred two mouse strains, attained a new strain nearly identical to one of the progenitor strains, but differing crucially in histocompatibility—that is, tissue compatibility upon transplantation—and thereupon identified an MHC locus. Later Jean Dausset demonstrated the existence of MHC genes in humans and described the first human leucocyte antigen, the protein which we call now HLA-A2. Some years later Baruj Benacerraf showed that polymorphic MHC genes not only determine an individual's unique constitution of antigens but also regulate the interaction among the various cells of the immunological system. These three scientists have been awarded the 1980 Nobel Prize in Physiology or Medicine for their discoveries concerning "genetically determined structures on the cell surface that regulate immunological reactions". The first fully sequenced and annotated MHC was published for humans in 1999 by a consortium of sequencing centers from the UK, USA and Japan in Nature. It was a "virtual MHC" since it was a mosaic from different individuals. A much shorter MHC locus from chickens was published in the same issue of Nature. Many other species have been sequenced and the evolution of the MHC was studied, e.g.
The parasagittal (Greek πᾰρᾰ́ (pará), beside) or paramedian or sagittal planes (Latin sagitta, arrow), which include the median or midsagittal plane and divide the body into left and right (in reference to the subject and not the observer). The frontal or coronal plane (Latin corona, crown), which divide the body into front and back. The axial or horizontal or transverse plane (Latin trans, across; vetere, to turn), which is perpendicular to the other two planes. The transpyloric plane, the subcostal plane, and the transumbilical plane planes are also considered in the division of the torso into the quadrants and regions of the abdomen. The three main axes of a human are the left-right (or horizontal or frontal), the craniocaudal (or rostrocaudal, longitudinal, or cephalocaudal), and the anteroposterior (or dorsoventral or sagittal) axes. Other anatomical lines include the axillary lines, parasternal line, and scapular line.
=== Among male homosexuals === A study undertaken at Utrecht University found that the majority of gay men in the study regarded a large penis as ideal, and having one was linked to self-esteem. One study analysing the self-reported Kinsey data set found that the average penis of a homosexual man was larger than the average penis of their heterosexual counterparts (6.32 inches [16.05 cm] in length amongst gay men versus 5.99 in [15.21 cm] in heterosexuals, and 4.95 inches [12.57 cm] circumference amongst gay men versus 4.80 in [12.19 cm] in heterosexual men).
Ram Krishna Nagar State assembly constituency is one of the 126 state legislative assembly constituencies in Assam, India. It is one of the six assembly segments that constitute the Karimganj Lok Sabha constituency. Since 2019, it has been represented by Bijoy Malakar of the Bharatiya Janata Party. Originally established as Ratabari in 1962, the constituency was redrawn during the 2023 delimitation exercise and was renamed to Ram Krishna Nagar. The reconstituted constituency now includes Ramkrishna Nagar town, and many other rural areas of the Sribhumi district.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。